Home Online Features Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
HO
Press Releases
February 7, 2025

Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years

By Eli Lilly and Company

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment

bradford

The Bradford Era

email
Local & Social